Format

Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):1189-1193. doi: 10.1051/medsci/2019212. Epub 2020 Jan 6.

[Names and indications of antibodies facing regulations and pharmaceutical company practices].

[Article in French; Abstract available in French from the publisher]

Author information

1
CHRU de Tours, 37000 Tours, France - UMR 1253, iBrain, Université de Tours, Inserm, 37000 Tours, France.
2
CHRU de Tours, 37000 Tours, France - EA 7501 - Groupe Innovation et ciblage cellulaire (GICC), Université de Tours, 37000 Tours, France.

Abstract

in English, French

The names and therapeutic indications of monoclonal antibodies must comply with current regulations, which does not prevent the development of commercial strategies around trade names. Some of these practices are based on territorial or legal considerations while others are motivated by real medical concerns. Finally, some of these have a significant financial impact on the community.

PMID:
31903936
DOI:
10.1051/medsci/2019212

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center